Deal Flow in 2022 Returned to pre-2019 Levels
Lower Deal Dollars Across All Healthcare and Life Sciences
Licensing Terms are Shifting to More in Milestones
Large Cap Biopharma In-Licensing and Buying in 2022
Big Pharma Pays Well for Phase II as POC Returns
Large Cap Biopharma Therapy Areas and Modalities in Focus
R&D Partnership Activity in Oncology
R&D Partnership Activity in Neurology
R&D Partnership Upfronts in the Top Modalities
Healthcare and Life Sciences Venture Returned to pre-2020
All Company Stages Saw Lower Venture Activity
Biopharma M&A Volume Increased in Q1
